image credit: Adobe Stock

Bayer reports positive early data for Parkinson’s cell therapy

August 28, 2023

Estimates hold that around half a million people in the U.S. have Parkinson’s, though, due to underdiagnosis or misdiagnosis, some believe the true number is much higher. The disease causes nerve cells in the part of the brain that controls movement to die or become impaired.

Many of the medicines used to treat Parkinson’s symptoms revolve around dopamine, a chemical messenger that plays a role in a variety of essential functions, including motor function. Bluerock’s therapy targets this chemical as well, but in a way different from currently available treatments, as it’s meant to replace the dopamine-making nerve cells that are lost in Parkinson’s patients.

Read More on Biopharma Dive